Thomas Weisel Upgrades Genomic Health (GHDX) to Overweight
GHDX Hot Sheet
Rating Summary:4 Buy, 6 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Thomas Weisel upgrades Genomic Health (Nasdaq: GHDX) from Marketweight to Overweight. Price target $23.
To see more analyst ratings on GHDX Click Here.
Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer.
To see more analyst ratings on GHDX Click Here.
Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer.
You May Also Be Interested In
- UPDATE: Williams Financial Group Upgrades Semtech Corp. (SMTC) to Buy; Check Again...Quarter Was Fairly Strong
- Macquarie Upgrades SBA Communications (SBAC) to Outperform
- Deutsche Bank Upgrades Siemens (SI) to Buy; Subtle Shift
Create E-mail Alert Related Categories
UpgradesRelated Entities
Thomas Weisel Partners GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
